FDA requirement AI medical device website bilingual clinical statement

On July 16, 2026, in response to the online information display requirements for AI-assisted diagnostic and remote monitoring medical devices exported to the U.S., the FDA issued a new enforcement signal. This adjustment is not aimed at the product registration itself, but rather at how clinical performance statements are presented on a company’s B2B independent website. It involves Chinese manufacturers that have already obtained 510(k) or De Novo authorization, and it will also extend to procurement review, compliance review, external sales material management, and pre-order communication. Therefore, relevant companies should promptly include this in their compliance review scope.

What Exactly Does This Update Require?

Confirmed information shows that on July 16, 2026, the FDA updated the Digital Health Center of Excellence guidance. According to this update, all Chinese manufacturers of AI-assisted diagnostic and remote monitoring medical devices exporting to the United States, if they have already obtained 510(k) or De Novo authorization, must present FDA-recognized clinical performance statements on their B2B independent websites in both Chinese and English side by side.

At the same time, the English version of the clinical performance statement must also be verified against the FDA-designated terminology database. The confirmed information also indicates that the above requirements apply to relevant authorized companies; if they are not met, there may be a risk that the purchaser refuses the products or that an FDA warning letter is issued.

The Impact Is First Felt in Website Presentation and Procurement Review

For Export Manufacturers, the Website Has Become a Compliance Trigger

For Chinese manufacturers directly targeting the U.S. market, the most immediate effect of this change is on B2B independent website content management. In the past, websites were more often seen as tools for market presentation and customer communication, but under this requirement, the language versions of clinical performance statements, side-by-side display format, and English terminology wording will all become part of compliance review. What companies need to pay attention to is not only whether related content has been published, but also whether the website content is consistent with the already authorized clinical performance statements.

For Buyers, the Early Review Criteria May Tighten

From the procurement side, the confirmed information has already pointed to the possibility that non-compliance could lead to buyer rejection. This means that in supplier screening, qualification review, and pre-order review, buyers may use the website’s public information as one of the verification bases. For sellers, whether the website pages, English statements, and technical materials provided externally are consistent will directly affect procurement communication efficiency and trust judgment.

For Certification and Compliance Support, the Pressure on Material Coordination Is Rising

Analysis suggests that the teams or external service providers responsible for registration, compliance review, technical document organization, and external material management are also affected. This requirement directly ties “website presentation” to “authorized clinical performance statements,” meaning that registration materials, market materials, and sales materials need to be more consistent. In particular, the English version must pass verification against the designated terminology database, which makes terminology usage a key item requiring close checking.

What Operational Changes Need Immediate Attention?

First, Verify Whether the Clinical Performance Statement Matches the Authorization Information

The first thing companies should focus on is whether the clinical performance descriptions for AI-assisted diagnostic or remote monitoring products shown on the website are consistent with the FDA-recognized content. The key issue is not only translation accuracy, but also whether any wording exceeds the authorized scope. If the online descriptions do not match the authorization basis, risks may arise later in procurement review or regulatory communication.

The English Terminology on the Website Can No Longer Follow Marketing Copy Logic Alone

According to the confirmed information, the English version must be verified against the FDA-designated terminology database. This means the English pages should not be written only according to marketing or website-building habits, but should be incorporated into a compliance review process. Companies need to pay special attention to whether the actual page presentation of English terminology, clinical performance descriptions, and side-by-side bilingual display meets the requirements.

Companies That Already Hold 510(k) or De Novo Authorization Also Need a Review

This requirement applies to companies that have already obtained 510(k) or De Novo authorization, so attention should not be limited to new projects preparing to enter the U.S. market. Companies with existing products, existing independent websites, and existing English introduction pages should also review whether their current pages meet the new display requirements, so as to avoid leaving compliance gaps on existing pages.

Procurement, Delivery, and Pre-Sales Materials Need to Be Adjusted in Sync

Analysis shows that companies should also pay attention to the consistency between website content and quotation materials, product introductions, and procurement document response materials. Because the confirmed information mentions the risk of buyer rejection, if the public website content and pre-sales document channels are inconsistent in actual execution, order advancement, pre-delivery confirmation, and customer review progress may be affected. At this stage, it is more appropriate to sort out material versions in advance rather than make corrections only after objections are raised by customers.

This Feels More Like a Signal of Channel Shift

From an industry perspective, the key point of this information is not only “bilingual display” itself, but that regulatory concerns have already extended to the company’s public information interface. It seems more like the compliance boundary of clinical performance statements is moving further from submission and authorization documents to the external display interface. For AI-assisted diagnostic and remote monitoring products, websites are no longer just a marketing entry point; they may also become an information interface observed jointly by procurement and regulators.

At the same time, this change is better understood as a rule-driven dynamic with clear implementation direction, rather than a general verbal reminder. The reason is that the applicable targets, display format, and English terminology verification requirements have all been specified. However, at the practical implementation level, the industry still needs to continue observing the subsequent execution channels, page review standards, the standards adopted by buyers, and the timing of corporate adjustments.

How Should the Industry Interpret This?

Taken together, this update reflects that the compliance requirements for AI medical devices exported to the U.S. are extending into public information management. It affects not only the website language format, but also whether clinical performance statements can remain aligned across sales, procurement, and regulatory communication. At present, it is more appropriate to understand this news as a practical compliance reminder and execution signal for already authorized companies, rather than as a simple information disclosure optimization requirement.

Basis of This Article and Follow-up Review Direction

This article was generated based on the user-provided news headline, event time, and event summary. The basis of the content is “New FDA rules for AI medical device websites in the U.S.: Chinese websites must provide an English clinical statement in sync,” the date “2026-07-16,” and related summary information. For such events, it is usually still necessary to combine regulatory agency releases, official announcements, industry association information, standard organization documents, trade and procurement-side public requirements, and ongoing verification in authoritative media reports.

Because no specific official source link was provided in the input, this article does not reference a specific link, and the relevant details still need to be based on subsequent public documents. Follow-up points worth continued observation include: whether enforcement details are further clarified, whether certification and compliance review channels are refined, whether procurement documents are adjusted in sync, and whether new consensus emerges in industry feedback and corporate implementation.